12 High-Growth Micro-Cap Stocks to Buy Now

10. Insight Molecular Diagnostics Inc. (NASDAQ:IMDX)

Market Capitalization: $183.41 Million

Expected 5-Year Earnings Growth: 21.77%

Number of Hedge Fund Holders: 8

Stock Upside Potential: 87.17%

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in the American Journal of Transplantation of new data demonstrating the statistical superiority of its flagship GraftAssure transplant rejection monitoring assay. The study showed that the novel GraftAssure Combination Model (CM)‑score, which integrates relative and absolute DNA fragment measurements, strongly correlates with kidney transplant rejection, confirming its reliability over non‑rejection cases.

First presented at the World Transplant Congress in 2025, the findings highlight the assay’s potential to help physicians distinguish rejection from other causes of organ damage, offering unprecedented diagnostic power. The data and its implications will be further discussed at the American Transplant Congress in Boston from June 20–24, 2026.

Meanwhile, BTIG reiterated its Neutral rating on May 15, awaiting FDA approval of GraftAssureDx, the company’s test kit designed to expand access to kidney transplant monitoring in a $2 billion‑plus market. With faster turnaround times and international appeal, GraftAssureDx could be transformative, though competition from established lab testing firms and the need to strengthen global strategy remain challenges.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is a precision diagnostics company that develops and commercializes blood-based tests, laboratory services, and testing kits. Their primary focus is democratizing molecular diagnostic testing in transplant care and oncology.